ACTUATE THERAPEUTICS, INC.
ACTUNasdaq
$1.44
↓ -13.3%Jul 17 close · end-of-day
Price
1Y↓ -76.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$33.9M
Enterprise Value
$25.8M
P/E
—
P/S
—
P/B
9.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$21.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-569.1%
ROIC
—
Debt / Equity
—
Net Cash
$8.1M
Return 1Y
-77.0%
Company profile
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We were incorporated in Delaware on January 16, 2015, as Apotheca Therapeutics, Inc. and changed our name to Actuate Therapeutics, Inc. on October 1, 2015. Our principal executive offices are located at 1751 River Run, Suite 400, Fort Worth, Texas.
- CEO
- Daniel M. Schmitt
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Texas
- Website
- actuatetherapeutics.com
Management & directors
- Schmitt Daniel MPresident, CEO and Director
Roles derived from SEC Form 4 filings.
Earnings
ACTU Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.24↓ -25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$25.0M | -$25.2M | -$22.5M |
| Net income | -$24.7M | -$27.3M | -$22.2M |
| Diluted EPS | -$17.24 | -$3.26 | -$1.06 |
| Operating cash flow | -$21.6M | -$21.8M | -$19.2M |
| Free cash flow | — | — | — |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.4M | -$5.4M | -$6.6M | -$6.4M | -$6.0M | -$5.5M | -$4.7M | -$5.7M |
| Net income | -$6.6M | -$6.0M | -$6.4M | -$6.3M | -$5.9M | -$5.4M | -$4.6M | -$5.6M |
| Diluted EPS | -$4.20 | -$0.55 | $6.89 | -$0.32 | -$0.30 | -$0.25 | -$0.19 | -$0.24 |
| Operating cash flow | -$2.7M | -$9.1M | -$4.8M | -$4.6M | -$4.2M | -$6.7M | -$3.7M | -$5.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-13 | SCHMITT DANIEL M· President, CEO and Director | Tax withholding | 121,874 | $4.33 | $527,714.42 | filing |
| 2026-02-13 | SCHMITT DANIEL M· President, CEO and Director | Option exercise | 272,055 | $0.00 | $0.00 | filing |
| 2026-01-05 | THOMSON TODD S | Sale | 280,000 | $5.80 | $1.6M | filing |
| 2025-06-27 | Bios Equity COF, LP | Buy | 71,428 | $7.00 | $499,996.00 | filing |
| 2025-06-27 | Kreis Leslie W. | Buy | 71,428 | $7.00 | $499,996.00 | filing |
| 2025-06-27 | Fletcher Aaron G.L. | Buy | 71,428 | $7.00 | $499,996.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.